Nothing is Better Than Agenus Inc. (AGEN) stock at the moment

Agenus Inc. (NASDAQ: AGEN) stock fell -2.53% on Friday to $2.70 against a previous-day closing price of $2.77. With 5.94 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.35 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.8600 whereas the lowest price it dropped to was $2.6300. The 52-week range on AGEN shows that it touched its highest point at $3.37 and its lowest point at $1.25 during that stretch. It currently has a 1-year price target of $8.26. Beta for the stock currently stands at 1.32.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGEN was down-trending over the past week, with a drop of -5.92%, but this was up by 16.88% over a month. Three-month performance surged to 4.25% while six-month performance fell -5.26%. The stock lost -3.91% in the past year, while it has gained 12.50% so far this year. A look at the trailing 12-month EPS for AGEN yields -0.80 with Next year EPS estimates of -0.72. For the next quarter, that number is -0.21. This implies an EPS growth rate of 90.00% for this year and 6.50% for next year.

Float and Shares Shorts:

At present, 286.85 million AGEN shares are outstanding with a float of 244.08 million shares on hand for trading. On Oct 13, 2022, short shares totaled 18.6 million, which was 6.57% higher than short shares on Sep 14, 2022. In addition to Dr. Garo H. Armen Ph.D. as the firm’s Founder, Exec. Chairman & CEO, Ms. Christine M. Klaskin serves as its VP of Fin., Principal Financial Officer & Principal Accounting Officer.

Institutional Ownership:

Through their ownership of 53.15% of AGEN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 7.91% of AGEN, in contrast to 29.78% held by mutual funds. Shares owned by individuals account for 24.23%. As the largest shareholder in AGEN with 8.64% of the stake, Deep Track Capital LP holds 26,325,000 shares worth 26,325,000. A second-largest stockholder of AGEN, The Vanguard Group, Inc., holds 22,201,311 shares, controlling over 7.28% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in AGEN, holding 20,325,943 shares or 6.67% stake. With a 5.63% stake in AGEN, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 17,173,892 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.92% of AGEN stock, is the second-largest Mutual Fund holder. It holds 8,886,270 shares valued at 21.33 million. iShares Russell 2000 ETF holds 2.20% of the stake in AGEN, owning 6,711,437 shares worth 16.11 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGEN since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGEN analysts setting a high price target of $8.30 and a low target of $5.00, the average target price over the next 12 months is $6.83. Based on these targets, AGEN could surge 207.41% to reach the target high and rise by 85.19% to reach the target low. Reaching the average price target will result in a growth of 152.96% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AGEN will report FY 2022 earnings on 02/27/2024. Analysts have provided yearly estimates in a range of -$0.72 being high and -$0.88 being low. For AGEN, this leads to a yearly average estimate of -$0.77. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Agenus Inc. surprised analysts by -$0.00 when it reported -$0.19 EPS against a consensus estimate of -$0.19. The surprise factor in the prior quarter was $0.06. Based on analyst estimates, the high estimate for the next quarter is -$0.19 and the low estimate is -$0.23. The average estimate for the next quarter is thus -$0.21.

Summary of Insider Activity:

Insiders traded AGEN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *